"Anticoagulants" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that prevent BLOOD CLOTTING.
| Descriptor ID |
D000925
|
| MeSH Number(s) |
D27.505.954.502.119
|
| Concept/Terms |
Anticoagulants- Anticoagulants
- Anticoagulation Agents
- Agents, Anticoagulation
- Anticoagulant Agents
- Agents, Anticoagulant
- Anticoagulant Drugs
- Drugs, Anticoagulant
- Anticoagulant
|
Below are MeSH descriptors whose meaning is more general than "Anticoagulants".
Below are MeSH descriptors whose meaning is more specific than "Anticoagulants".
This graph shows the total number of publications written about "Anticoagulants" by people in this website by year, and whether "Anticoagulants" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 3 | 0 | 3 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 2 | 1 | 3 |
| 2004 | 3 | 0 | 3 |
| 2005 | 1 | 4 | 5 |
| 2006 | 2 | 0 | 2 |
| 2007 | 2 | 1 | 3 |
| 2008 | 3 | 2 | 5 |
| 2009 | 4 | 2 | 6 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 3 | 3 | 6 |
| 2013 | 4 | 0 | 4 |
| 2014 | 3 | 4 | 7 |
| 2015 | 4 | 2 | 6 |
| 2016 | 5 | 3 | 8 |
| 2017 | 6 | 1 | 7 |
| 2018 | 2 | 3 | 5 |
| 2019 | 3 | 1 | 4 |
| 2020 | 1 | 4 | 5 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 4 | 4 |
| 2023 | 1 | 6 | 7 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anticoagulants" by people in Profiles.
-
Levels of procoagulant factors and peak thrombin generation in relation to dementia risk in older adults: The Cardiovascular Health Study. Thromb Res. 2024 Mar; 235:148-154.
-
Gaps in guideline-recommended anticoagulation in patients with atrial fibrillation and elevated thromboembolic risk within an integrated healthcare delivery system. BMC Cardiovasc Disord. 2023 11 21; 23(1):578.
-
Prevalence of and Eligibility for Surveillance Without Anticoagulation Among Adults With Lower-Risk Acute Subsegmental Pulmonary Embolism. JAMA Netw Open. 2023 08 01; 6(8):e2326898.
-
Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism. JAMA Netw Open. 2023 08 01; 6(8):e2328033.
-
Association of Direct Oral Anticoagulation Management Strategies With Clinical Outcomes for Adults With Atrial Fibrillation. JAMA Netw Open. 2023 Jul 03; 6(7):e2321971.
-
Effectiveness and safety of Dabigatran 110 mg versus 150 mg for Stroke Prevention in Patients with Atrial Fibrillation at High Bleeding Risk. Clin Ther. 2023 07; 45(7):e151-e158.
-
Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial. Circulation. 2023 06 20; 147(25):1891-1901.
-
Clinical decision support to Optimize Care of patients with Atrial Fibrillation or flutter in the Emergency department: protocol of a stepped-wedge cluster randomized pragmatic trial (O'CAF? trial). Trials. 2023 Mar 31; 24(1):246.
-
The intensity of anticoagulant dosing in hospitalized patients with COVID-19: An observational, comparative effectiveness study. J Hosp Med. 2023 01; 18(1):43-54.
-
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding. J Thromb Thrombolysis. 2022 Oct; 54(3):470-479.